Form 4: NextCure Executive Kevin G. Shaw Reports Stock Option Grant
SEC Form 4 Filing
Kevin G. Shaw, Sr VP and General Counsel of NextCure, Inc., reports the acquisition of 93,900 stock options.
Summary
- On March 29, 2024, Kevin G. Shaw, Sr VP, General Counsel of NextCure, Inc., acquired 93,900 employee stock options with an exercise price of $2.23.
- The options vest fully on March 29, 2025.
- Following the transaction, Shaw directly owns 93,900 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a standard disclosure of stock options granted to an executive.
Positives
- The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and value creation.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. This filing indicates compensation practices at NextCure.
Stakeholder Impact
- The stock option grant aligns the executive's interests with those of shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/29/2024 | Date of the stock option grant. |
| 03/29/2025 | Date the stock options fully vest. |
| 03/28/2034 | Expiration date of the stock options. |
| 04/02/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.